Omeros announces FDA approved YARTEMLE for treatment of TA-TMA

Omeros (OMER) announced that the U.S. Food and Drug Administration, FDA, has approved YARTEMLE for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy, TA-TMA, a complication of stem-cell transplantation driven by activation of the lectin pathway of complement. YARTEMLEA is the first and only approved lectin pathway inhibitor. YARTEMLEA selectively inhibits MASP-2, blocking pathway activation while preserving classical and alternative complement functions. YARTEMLEA is approved for use in adults and in children ages two years and older.